Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Ezetimibe/Atorvastatin FDC vs Co-administration in Primary Hypercholesterolemia
NCT01370603Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Sep 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin + ezetimibe in hypercholesterolemia (2 arms), sponsored by Organon & Co. Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol at 6 weeks. Started Sep 2011; status: completed.
02
Drugs
atorvastatin + ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01370603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370603.